Vitreous is very stable in highly acidic and alkaline conditions

Article

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts.

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts, according to a study published in the January issue of Retina.

Mandi Conway and colleagues from the University of Arizona College of Medicine, Department of Ophthalmology and Vision Science, Tucson, USA carried out a study to measure the buffering capacity of bovine vitreous to hydrogen chloride (HC1), sodium hydroxide (NaOH) and triamcinolone acetonide.

Vitreous was dissected from 10 bovine globes, homogenized and divided into 5 mL aliquots. The carbonate/bicarbonate buffer of the vitreous was maintained by performing all subsequent titrations under an atmosphere of 5% CO2/95% air. The pH was monitored during the addition of 0.1 N HC1, 0.1 N NaOH or 40 mg/mL triamcinolone acetonide to the vitreous sample; 0.9% NaC1 was used as a control.

The researchers found that the buffering capacity of bovine vitreous to HC1 was 10 times greater than that of 0.9% NaC1 and that the buffering capacity of vitreous to NaOH was four times greater than that of 0.9% NaC1. It was also discovered that bovine vitreous was able to resist pH changes from addition of triamcinolone acetonide at levels 20 time greater than commonly injected intravitreally.

The results of this study indicate that vitreous is more capable of remaining stable when acidic or alkaline pharmaceuticals are injected into it.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.